Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT00993460

Study of Changes in Skeletal Muscle After Caloric Restriction

Diacylglycerols and Insulin Action in Skeletal Muscle Upon Caloric Restriction

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
24 (estimated)
Sponsor
Vanderbilt University · Academic / Other
Sex
Female
Age
21 Years – 65 Years
Healthy volunteers
Accepted

Summary

Research has shown that fat stored within muscles affects the muscle's sensitivity to insulin and ability to handle blood glucose. The purpose of this study is to examine the effects of weight loss surgery-induced caloric restriction on the accumulation and types of fats within skeletal muscle, as well as the effects of such caloric restriction on insulin sensitivity and inflammatory responses in skeletal muscle. The investigator proposes that caloric restriction will result in decreases in diacylglycerols enriched with saturated fat and increases in diacylglycerols enriched with monounsaturated fats.

Detailed description

We hypothesize that in a setting of surgically-induced weight loss decrements in select DAGs result in improved glucose utilization, altered insulin signaling and decreased inflammatory responses. We propose to examine the impact of molecular DAG species accumulation on glucose utilization, insulin signaling and inflammation in skeletal muscle from morbidly obese subjects before/after 10% weight loss facilitated by Roux-en-Y Gastric Bypass (RYGB). We will compare these results to those from a control, normal weight cohort The detected differences in DAG molecular species, insulin action, inflammatory responses between normal and obese subjects (before/after weight loss) will emphasize pathways coordinately altered as a consequence of adiposity and RYGB surgery. The primary endpoints for this study will be: Insulin sensitivity (glucose Rd, insulin levels, DAG mass, DAG species amounts).Secondary endpoints will be: FFA levels, inflammatory cytokine production, and insulin signaling in skeletal muscle.

Conditions

Timeline

Start date
2011-03-01
Primary completion
2013-11-01
Completion
2026-11-01
First posted
2009-10-12
Last updated
2025-07-08

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00993460. Inclusion in this directory is not an endorsement.